#China #Suzhou #siRNA #RiboPepSTAR #RiboLife

Ribo Life Science's Innovative Approach to siRNA Delivery

Suzhou Ribo Life Science Co., Ltd., often referred to simply as Ribo, made waves in the pharmaceutical sector by introducing their groundbreaking technology, RiboPepSTAR™, which significantly enhances the ability to administer small interfering RNA (siRNA) beyond the liver. This advancement was highlighted during their presentation at the RNA Leaders Europe Conference held in Vienna, Austria, on March 19, 2026.

The Journey of Ribo Life Science

The company, listed on the Hong Kong Stock Exchange under the code 6938, has previously marked its success with RiboGalSTAR™, a platform that supports seven clinical programs and has attracted substantial global partnerships amounting to over $6 billion. Building on this momentum, Ribo is now focusing on expanding drug delivery capabilities that target organs outside the liver, thus broadening the horizon for various therapeutic applications.

Breakthroughs with RiboPepSTAR™ Technology

The proprietary RiboPepSTAR™ technology allows for precise targeting of siRNA to crucial organs such as the kidneys and heart. Preclinical studies have shown promising results, including:
- Kidney Targeting: RiboPepSTAR™ demonstrated selective uptake by proximal tubular cells across various animal models. An impressive knockdown (KD) of the target gene was achieved, boasting rates as high as 80% in species ranging from rodents to non-human primates (NHPs). Notably, the findings were validated in several disease models, such as Type 2 diabetes, showcasing effective renal-specific reductions in targeted biomarkers.
- Heart Targeting: Ribo’s heart-specific conjugate resulted in sustained KD within cardiac tissue during mouse model trials. Importantly, minimal effects were observed in skeletal muscle, while liver and kidney activity remained negligible, confirming strong heart specificity.
- Fat Tissue Targeting: Current administration techniques allowed for effective adipose targeting in non-human primates, achieving an extraordinary 96% KD, showcasing Ribo's potential in metabolic disorders.

These results highlight the vast therapeutic potential of RiboPepSTAR™ in addressing renal, cardiovascular, and metabolic diseases.

Advancing Multi-Target siRNA Platforms

In conjunction with RiboPepSTAR™, the company is driving advancements in its multi-target siRNA platform, empowering the simultaneous silencing of multiple genes with a single molecule. Ribo’s dual-target siRNAs are achieving comparable knockdown levels to their single-target counterparts, enabling synergistic modulation of signaling pathways and enhancing therapeutic benefits through a singular drug.

Commitment to Global Healthcare

Ribo's innovative platforms for extrahepatic and multi-target siRNA delivery pave the way for top-tier therapies across a broad range of diseases. This aligns with Ribo's steadfast commitment to making next-generation siRNA medications accessible to patients worldwide, ultimately working towards the improvement of global healthcare outcomes.

As Ribo Life Science continues to innovate, their efforts in targeting drug delivery signal a promising future for RNA-based therapies, setting a foundation that other biotechnology firms can aspire to follow. Their dedication to research and collaboration highlights the dynamic nature of the pharmaceutical landscape, promising exciting developments ahead for patients and practitioners alike.

Conclusion

With RiboPepSTAR™, Ribo Life Science is not just improving drug delivery; they are reshaping the narrative around siRNA-based therapies. Their strides towards effective organ-targeted treatments mark a significant leap forward in the quest to tackle complex diseases, offering hope where it is most needed.